8-K: Invivyd Secures $30 Million Loan Facility with Silicon Valley Bank

Invivyd, Inc. has entered into a $30 million term loan agreement with Silicon Valley Bank to bolster its financial flexibility ahead of key milestones.

Summary

• Invivyd, Inc. has entered into a Loan and Security Agreement with Silicon Valley Bank for a term loan facility of up to $30 million.
• The facility is divided into three tranches: Term A Loans (up to $10 million available from August 15, 2025, to December 31, 2026), Term B Loans (up to $10 million), and Term C Loans (up to $10 million), both available upon achieving certain net product revenue milestones and ending on June 30, 2027.
• The funds will be used for working capital and general business purposes.
• The loans mature on March 1, 2029, and bear interest at a rate equal to the greater of (x) the Wall Street Journal prime rate minus 0.25% (subject to a 9.00% cap) and (y) 6.00%.
• Principal repayment begins on April 1, 2027, in 24 equal monthly installments, potentially extended to April 1, 2028, with 12 installments upon achieving certain net product revenue milestones.
• A final payment fee of 4.50% of the aggregate principal amount of the loans is due at maturity or earlier prepayment.
• The agreement includes an unused term loan commitment fee of 1.00% of the Term Facility, which may be waived if loans are funded before July 1, 2027.
• Voluntary prepayments are allowed, subject to prepayment premiums ranging from 0% to 3.0% based on when the prepayment occurs.
• The loan is secured by substantially all of the Company's assets, excluding intellectual property.
• The Loan Agreement contains financial covenants, including minimum net product revenue and either minimum EBITDA or minimum unrestricted cash and cash equivalents.
• Minimum Net Product Revenue targets begin at $[***] for the quarter ending June 30, 2025, and increase to $[***] by December 31, 2026.
• Minimum EBITDA targets begin at $[***] for the quarter ending September 30, 2025, and increase to $[***] by December 31, 2026.
• The Minimum Cash Threshold is defined as the greater of (x) the sum of the Company's six-month Cash Burn and the aggregate amount of loans outstanding under the Term Facility and (y) the aggregate amount of loans outstanding under the Term Facility multiplied by two.
• The company announced the loan facility in a press release on April 21, 2025.

Sentiment

Score: 7

Explanation: The sentiment is positive as the company has secured a significant loan facility to support its operations and pipeline development. The non-dilutive nature of the financing is also a positive factor. However, the presence of financial covenants and the secured nature of the loan introduce some risks.

Positives

• The $30 million loan facility provides Invivyd with additional financial resources.
• The non-dilutive nature of the financing preserves per-share value for existing shareholders.
• The loan structure allows for drawdown of capital in the future if certain conditions and milestones are met.
• The agreement provides flexibility for working capital and general business purposes.

Negatives

• The loan is secured by substantially all of the company's assets, excluding intellectual property, which could limit financial flexibility in the future.
• The Loan Agreement contains financial covenants, including minimum net product revenue and either minimum EBITDA or minimum unrestricted cash and cash equivalents, which could restrict the company's operations if not met.
• The company is subject to prepayment penalties if the loan is prepaid before the third anniversary of the closing date.

Risks

• Failure to meet financial covenants could trigger an event of default, allowing the lender to accelerate the loan.
• The variable interest rate exposes the company to interest rate risk.
• The need to achieve certain net product revenue milestones to access Term B and Term C loans introduces uncertainty.
• The company's assets are pledged as collateral, which could be seized in the event of default.

Future Outlook

The company intends to use the loan facility to support its pipeline candidate, VYD2311, and focus on per-share value creation.

Management Comments

• Bill Duke, Chief Financial Officer of Invivyd, stated, 'We are pleased to have secured this term loan facility ahead of important anticipated catalysts, including gaining alignment with the FDA on the regulatory pathway of our pipeline candidate, VYD2311.'
• He added, 'The non-dilutive nature of this financing facility supports balance sheet optionality so the company can focus on per-share value creation.'

Industry Context

Biopharmaceutical companies often utilize loan facilities to fund research and development activities, especially when approaching key regulatory milestones. This financing provides Invivyd with capital without diluting existing shareholders.

Comparison to Industry Standards

• Similar to other biotech companies, Invivyd is using debt financing to fund its operations.
• Comparable companies like Vir Biotechnology and Regeneron have also used debt financing to support their research and development efforts.
• The interest rate and financial covenants are typical for venture-backed companies in the biotech industry.
• The loan is secured by the company's assets, which is a common practice in such financings.

Stakeholder Impact

• Shareholders benefit from the non-dilutive nature of the financing.
• Employees benefit from the company's increased financial stability.
• Customers may benefit from the company's ability to develop and commercialize new products.

Next Steps

• Invivyd intends to use the proceeds of the Term Facility for working capital and general business purposes.
• The company anticipates gaining alignment with the FDA on the regulatory pathway of its pipeline candidate, VYD2311.

Key Dates

Keywords

Loan Facility, Silicon Valley Bank, Invivyd, Term Loan, Financial Covenants, Monoclonal Antibody, VYD2311, PEMGARDA, COVID-19, Financing